# CURRICULUM VITAE


| | |
|---|---|
| Nome: | **GIUSEPPE ALBERTO MARIA PALUMBO** |
| Luogo e data di nascita: | Catania, 2 Maggio 1965 |
| Stato Civile: | Coniugato, 2 figli |
| Posizione attuale: | Professore Ordinario di Malattie del Sangue<br>Settore Concorsuale 06/D3 – SSD MEDS-09/B (ex MED/15)<br>Università degli Studi di Catania |
| Indirizzo: | Azienda Ospedaliero-Universitaria<br>Policlinico "G. Rodolico" – San Marco - Catania<br>Unità Operativa di Ematologia con TMO<br>PO Rodolico - Pad. 8 CAST<br>Via S. Sofia, 78<br>95123 CATANIA |
| Telefono: | 095-3781960/1987 |
| Indirizzo abitazione: | Via Anfuso, 16<br>95126 CATANIA |
| Cellulare: | 328-342.3820 |
| e-mail | ga.palumbo@tiscali.it, palumbo.ga@gmail.com |
| Codice Fiscale: | PLM GPP 65E02 C351A |
| Iscrizione Ordine Medici | CT 9591 |
| ORCID | 0000-0003-1859-6319 |


**TITOLI E RICONOSCIMENTI**

| | |
|---|---|
| - Diploma di Maturità Classica | 1983 |
| - First Certificate in English,<br>University of Cambridge, Gran Bretagna | 1983 |
| - Certificate of Proficiency in English,<br>University of Cambridge, Gran Bretagna | 1984 |
| - Allievo interno, Istituto di Chimica Biologica,<br>Facoltà di Medicina e Chir., Università di Catania | 1984/85 |
| - Visiting student, Surgery Clinic of<br>Pomeranian Medical Academy Szczecin, Polonia | 1986 |
| - Visiting student, Gynecological Department of<br>Medical Academy in Szczecin, Polonia | 1986 |
| - Visiting student in Warsaw, Medical Academy, Polonia | 1987 |
| - Visiting student, Clinic of Internal Medicine<br>of the Medical Academy Szczecin, Polonia | 1987 |
| - Vincitore premio di studio Toscano-Scuderi<br>Facoltà di Medicina e Chirurgia<br>Università degli Studi di Catania | 1987/88 |
| - Allievo interno, Istituto di Farmacologia,<br>I Cattedra, Facoltà di Medicina e Chirurgia, | |

Università degli Studi di Catania 1988/89

- Partecipante al Corso Residenziale di Informatica
presso Novedrate (MI), IBM 1989

- Laurea in Medicina e Chirurgia
(tesi sperimentale in Neuroendocrino-
immunologia della Riproduzione)
110/110 e lode, proposta al premio Clementi,
Dignità di Stampa.
Università degli Studi di Catania 1989

- Servizio militare svolto in qualità di Ufficiale Medico
del Corpo Sanitario Aeronautico (CSA)
dell'Aeronautica Militare Italiana 1991

- Collaboratore dei periodici medico-scientifici
Corriere Medico, Cardio e Brain 1991-93

- Specializzazione in Allergologia ed Immunologia Clinica
(tesi sperimentale su PAF e meccanismi di flogosi),
70/70 e lode.
Università degli Studi di Milano 1992

- Vincitore Borsa di Studio per soggiorni di ricerca
scientifica presso istituzioni estere.
Università degli Studi di Milano 1992

- Visiting Scientist presso DNAX Research
Institute of Molecular and Cellular Biology,
Human Immunology Department, Palo Alto, CA, U.S.A. 1992

- Medico interno presso II Cattedra di Ematologia
dell'Università degli Studi di Catania 1993-97

- Vincitore premio "Santella Massimino"
Fondazione Catanese per lo Studio e la Cura
delle Malattie Neoplastiche del Sangue
per un contributo di rilevante interesse scientifico
presentato al 34° Congresso Nazionale S.I.E. 1993

- Visiting Scientist presso Hadassah Hospital,
Department of Hematology, Jerusalem, Israele 1994

- Vincitore di Borsa di studio dell'European
School of Oncology (ESO) per frequenza
1st Educational Forum on Leukemias 1994

- Visiting Scientist presso Hadassah Hospital,
Department of Hematology, Jerusalem, Israele 1996

- Specializzazione in Ematologia
(tesi sperimentale su Linfomi e inibitori delle proteino-kinasi),
50/50 e lode.
Università degli Studi di Catania 1996

- Visiting Scientist presso Department of Immunology,
Kochi Medical School, Japan 1997

- Stage in Ematologia
Hammersmith Hospital, Londra, Gran Bretagna 2001

- Dottorato in Patologia ed Ematologia Sperimentale
(tesi sperimentale su Nuove citochine nelle leucemie acute) 2002

- Dirigente Medico
U.O. Ematologia – A.O.U. “Policlinico-V.Emanuele” – Catania 1998-2017

- Professore Associato di Ematologia MED/15 — 2018-2024
  Università degli Studi di Catania

- Direttore della Scuola di Specializzazione in Ematologia — 2019-2022
  Università degli Studi di Catania

- Professore Ordinario di Ematologia MEDS-09/B — 2024
  Università degli Studi di Catania

**SOCIETA' SCIENTIFICHE**

È stato membro della International Society for NeuroImmunoModulation (ISNIM) nel periodo 1989-96, della Società Italiana di NeuroImmunoModulazione nel periodo 1992-96 ed è tuttora membro della Società Italiana di Ematologia (SIE) dal 1994, della Società Italiana di Ematologia Sperimentale (SIES) dal 1998. È stato membro della European Society of Haematology (EHA) nel 2008. Membro della Commissione Studi Biologici della Fondazione Italiana Linfomi (FIL), precedentemente Intergruppo Italiano Linfomi (IIL) dal 2008, anno della sua costituzione

**TEMI DI RICERCA AFFRONTATI**

Studi tesi ad esplorare le correlazioni fra Sistema Nervoso, Sistema Endocrino e Sistema Immunitario nonchè le relazioni di questi con il Sistema Riproduttivo, che sono stati oggetto della Tesi di Laurea e di numerose pubblicazioni su riviste scientifiche internazionali e comunicazioni a congressi nazionali ed internazionali.

Studi sui meccanismi di cronicizzazione e di guarigione dell'immunoflogosi allergica, con particolare attenzione alle cellule del sistema immunitario e non coinvolte nonchè al ruolo del PAF. Essi sono stati oggetto della Tesi di Specializzazione, di pubblicazioni su riviste scientifiche internazionali e di comunicazioni a congressi nazionali ed internazionali.

Studi sulle $\alpha$- e $\beta$-talassemie nella Sicilia Orientale. Correlazioni fra espressione fenotipica e genotipo. Rilievo dell'incidenza dei diversi genotipi dell'a-talassemia, con particolare attenzione a : $-(\alpha)^{20.5}$, - - Med, $-\alpha^{3.7}$, $-\alpha^{4.2}$, $\alpha\alpha\alpha$. Tali ricerche sono state effettuate con tecniche di biologia molecolari quali PCR e Southern Blot e si sono concluse all'interno di Progetti di Ricerca sulle Talassemie supportati dalla Regione Sicilia.

Studi di chemiosensibilità in vitro su cellule isolate da pazienti affetti da leucemie acute e croniche nonchè su linee cellulari, sia con farmaci già in commercio (in particolare fludarabina, mitoxantrone, alcaloidi della vinca, antracicline) che con molecole sperimentali (2-clorodesossiadenosina, gemcitabina, taxol, topotecan, tirfostine). I risultati di tali ricerche, che proseguono, sono stati oggetto di pubblicazioni su riviste scientifiche internazionali e di comunicazioni a congressi nazionali ed internazionali.

Studi sulla produzione ed il rilascio di citochine in condizioni fisiologiche ed in corso di malattie, con l'applicazione di tecniche di biologia molecolare fra cui la Polymerase Chain Reaction (PCR) semiquantitativa. I risultati di tali ricerche sono in fase di pubblicazione.

Studi concernenti la malattia minima residua (MRD) in leucemie e linfomi con tecniche di biologia molecolare. I risultati di tali ricerche, che proseguono con l'applicazione di nuove tecniche quali la Real-Time PCR, sono stati pubblicati su riviste scientifiche internazionali.

Studi sul ruolo di alcuni polimorfismi genici in grado di influenzare la risposta immunitaria, in particolare la antibody-dependent cell mediated cytotoxicity (ADCC) e la risposta a farmaci antitumorali quali gli anticorpi monoclonali. I risultati di tali ricerche sono stati oggetto di comunicazioni a congressi nazionali ed internazionali, in parte già pubblicati su riviste internazionali "peer-rewieved", pubblicati ed altri in corso di pubblicazione.

Studi su casistiche real-life di pazienti affetti da sindromi mieloproliferative croniche bcr\abl negative (MPN), e più in particolare da mielofibrosi (MF)

**DIDATTICA**

Partecipa attivamente alla vita dell'Istituto di Ematologia dell'Università di Catania. Ha tenuto numerosi seminari su argomenti di oncologia ematologica e sulla biologia molecolare applicata allo studio ed alla diagnostica di patologie ematologiche

Ha seguito studenti di Medicina e Chirurgia nella preparazione di Tesi di Laurea e specializzandi in Ematologia nella preparazione di tesi di Specializzazione. E' stato tutor degli istudenti afferenti alla Scuola di Specializzazione in Ematologia

Ha partecipato come docente a corsi di aggiornamento per medici di base, per specialisti e per informatori farmaceutici, per laureati in discipline scientifiche

Insegna Ematologia presso i Corsi di Studi di Medicina, di Biotecnologie, di Tecnici di Laboratorio Biomedico e di Tecniche di Fisiopatologia Cardiocircolatoria e Perfusione Cardiovascolare dell'Università degli Studi di Catania dall'A.A. 2018/19

Fa parte del Collegio dei Docenti del Dottorato di Ricerca in Biomedicina Traslazionale dell'Università dagli Studi di Catania

È stato Direttore della Scuola di Specializzazione in Ematologia dell'Università degli Studi di Catania per il quadriennio 2018-2021

Componente della Commissione Scientifica e docente al Master di I livello in Talassemia ed Emoglobinopatie dell'Università degli Studi di Catania tenutosi nell'A.A. 2022/2023

Ha tenuto lezioni e conferenze in congressi internazionali, ospedali e Università in Brasile, Canada, Colombia, Francia, Giappone, Hong-Kong (Cina), India, Israele, Romania, Russia, Svizzera e Taiwan

**ATTIVITA' ORGANIZZATIVA E VARIE**

Ha contribuito ad organizzare, è stato Responsabile Scientifico ed ha fatto parte della Segreteria Scientifica di numerosi Congressi Nazionali in ambito ematologico

Si è occupato dell'informatizzazione dell'U.O. di Ematologia dove lavora e ha curato il suo sito Internet

Socio fondatore, componente del Consiglio di Amministrazione e Segretario di A.I.L. – Associazione contro le Leucemie, i Linfomi ed il Mieloma – Sede di Catania

Componente del Comitato Scientifico di AiPaSiM ONLUS – Associazione dei pazienti di Mielodisplasia (MDS)

Refeee e editor per numerose importanti riviste internazionali in ambito ematologico ed oncologico

**LAVORI IN EXTENSO PRESENTI SU MEDLINE**

214. Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, Tiribelli M, Cavazzini F, D'Addio A, Tieghi A, Farina M, Cavalca F, Dedola A, Heidel FH, Palumbo GA, Rossi E, Branzanti F, De Stefano V.
**Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea.**
Leukemia. 2025 May 28. doi: 10.1038/s41375-025-02646-y. PMID: 40437171

213. Crisà E, Cilloni D, Riva M, Balleari E, Barraco D, Manghisi B, Borin L, Calmasini M, Calvisi A, Capodanno I, Della Porta MG, Diral E, Fattizzo B, Fenu S, Paolini S, Finelli C, Fozza C, Frairia C, Giai V, Turrini M, Isoni MA, Itri F, Maurillo L, Molteni A, Palumbo GA, Pelizzari AM, Pilo F, Poloni A, Bosi C, Sanpaolo G, Sancetta R, Amato C, Santini V, Voso MT, Salek S, Ionova T, Nosari A, Oliva EN.
**Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.**
Cancers (Basel). 2025 May 7;17(9):1587. doi: 10.3390/cancers17091587.PMID: 40361511

212. Chifotides HT, Duminuco A, Torre E, Vetro C, Harrington P, Palumbo GA, Bose P.
**Emerging Therapeutic Approaches for Anemia in Myelofibrosis.**
Curr Hematol Malig Rep. 2025 May 3;20(1):7. doi: 10.1007/s11899-025-00751-4.PMID: 40317385

211. Duminuco A, Novello G, Mauro E, Scalisi E, Del Fabro V, Sambataro D, Palumbo G, Di Raimondo F, Romeo D.
**Chemotherapy extravasation: diagnosis, prevention and management.**
J Chemother. 2025 Apr 9:1-13. doi: 10.1080/1120009X.2025.2488599. PMID: 40205769

210. Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Iurlo A, Lemoli RM, Cilloni D, Bocchia M, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F.
**Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis.**
Clin Lymphoma Myeloma Leuk. 2025 Mar 4:S2152-2650(25)00077-1. doi: 10.1016/j.clml.2025.02.015. PMID: 40133140

209. Harrison CN, Ross DM, Fogliatto LM, Foltz L, Busque L, Xiao Z, Heidel FH, Koehler M, Palumbo GA, Breccia M, Komatsu N, Kirito K, Xicoy Cirici B, Martinez-Lopez J, Rovo A, Petruk C, Bobirca C, Mirams L, McMillan A, Harper G, Kiladjian JJ.
**Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey.**
Hemasphere. 2025 Mar 24;9(3):e70106. doi: 10.1002/hem3.70106. eCollection 2025 Mar.PMID:

208. Palandri F, Inzoli A, Barone A, Dordoni D, Formenti E, Corradini D'Elia G, Rabsiun Aramburu VL, Palumbo GA, Breccia M.
**Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitals.**
Front Oncol. 2025 Mar 7;15:1549023. doi: 10.3389/fonc.2025.1549023. eCollection 2025.PMID: 40123903

207. Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, Sibilla S, Di Renzo N, Abruzzese E, Siragusa S, Crugnola M, Selleri C, Pane F, Sportoletti P, Martino B, Impera S, Ricco A, Langella M, Ditonno P, Carli G, Itri F, Liberati AM, Urbano T, Tafuri A, Polizzi V, Pastore D, Morsia E, Benevolo G, Micucci G, Farina G, Bonifacio M, Elli EM, Gardellini A, De Stefano V, Caocci G, Falcone AP, Vallisa D, Brociner M, Tiribelli M, Binotto G, Pocali B, Cavazzini F, Tomassetti S, Lunghi F, Di Ianni M, Allegra A, Anaclerio B, Mazzotta S, Orofino N, Gherlinzoni F, Castiglioni C, Landoni M, Valsecchi D, Magnoli M, Guglielmelli P, Passamonti F.
**Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).**
Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801.PMID: 40111826

206. Duminuco A, Bulla A, Rosso R, Romeo MA, Cambria D, La Spina E, Ximenes B, Giallongo C, Tibullo D, Romano A, Raimondo FD, Palumbo GA.
**Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.**
Vaccines (Basel). 2025 Jan 23;13(2):111. doi: 10.3390/vaccines13020111.PMID: 40006658

205. Oliva EN, Guo S, Lord-Bessen J, Yucel A, Latagliata R, Breccia M, Palumbo GA, Sanpaolo G, Riva M, Santini V, Platzbecker U, Garcia-Manero G, Fenaux P, Pelligra CG.
**Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms.**
Front Oncol. 2025 Feb 7;15:1507854. doi: 10.3389/fonc.2025.1507854. eCollection 2025.PMID: 39990686

204. Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, Beggiato E, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Scalzulli E, D'Agostino D, Caserta S, Nardo A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Palumbo GA, Breccia M, Elli EM, Bonifacio M.
**Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy.**
Ann Hematol. 2025 Jan;104(1):241-251. doi: 10.1007/s00277-025-06204-5. Epub 2025 Jan 20.PMID: 39831987

203. Spampinato M, Giallongo C, Giallongo S, Spina E, Duminuco A, Longhitano L, Caltabiano R, Salvatorelli L, Broggi G, Pricoco EP, Del Fabro V, Dulcamare I, DI Mauro AM, Romano A, Di Raimondo F, Li Volti G, Palumbo GA, Tibullo D.
**Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis.**
J Transl Med. 2025 Jan 14;23(1):69. doi: 10.1186/s12967-025-06083-4.PMID: 39810250

202. Duminuco A, Del Fabro V, De Luca P, Leotta D, Limoli MC, Longo E, Nardo A, Santuccio G, Petronaci A, Stanzione G, Di Raimondo F, Palumbo GA.
**Emergencies in Hematology: Why, When and How I Treat?**
J Clin Med. 2024 Dec 12;13(24):7572. doi: 10.3390/jcm13247572.PMID: 39768494

201. Oliva EN, Cuzzola M, Porta MD, Candoni A, Salutari P, Palumbo GA, Reda G, Iannì G, Zampini M, D'Amico S, Tripepi G, Capelli D, Alati C, Cannatà MC, Niscola P, Serio B, Barillà S, Musto P, Vigna E, Melillo LMA, Tripepi R, Zannier ME, Nannya Y, Ogawa S, Mammì C
**Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).**
Int J Mol Sci. 2024 Oct 30;25(21):11646. doi: 10.3390/ijms252111646.PMID: 39519198

200. Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri PP, Summa V, Guarcello A, Palumbo GA, Pane F, Guglielmelli P, Corradini P, Russo P
**The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries.**
Br J Haematol. 2024 Oct 3. doi: 10.1111/bjh.19812. PMID: 39363576

199. Tissino E, Gaglio A, Nicolò A, Pozzo F, Bittolo T, Rossi FM, Bomben R, Nanni P, Cattarossi I, Zaina E, Zimbo AM, Ianna G, Capasso G, Forestieri G, Moia R, Datta M, Härzschel A, Olivieri J, D'Arena G, Laurenti L, Zaja F, Chiarenza A, Palumbo GA, Martino EA, Gentile M, Rossi D, Gaidano G, Del Poeta G, Laureana R, Del Principe MI, Maity PC, Jumaa H, Hartmann TN, Zucchetto A, Gattei V.
**The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.**
Leukemia. 2024 Oct;38(10):2127-2140. doi: 10.1038/s41375-024-02376-7. Epub 2024 Aug 14. PMID: 39143370

198. Duminuco A, Au Yeung J, Vaghela R, Virdee S, Woodley C, Asirvatham S, Curto-Garcia N, Sriskandarajah P, O'Sullivan J, de Lavallade H, Radia D, Kordasti S, Palumbo G, Harrison C, Harrington P
**Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.**
Hemasphere. 2024 Aug 8;8(8):e143. doi: 10.1002/hem3.143. eCollection 2024 Aug.PMID: 39131900

197. Breccia M, Palandri F, Polverelli N, Caira M, Berluti M, Palumbo GA, De Stefano V.
**Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives.**
Front Oncol. 2024 Jul 24;14:1382872. doi: 10.3389/fonc.2024.1382872. eCollection 2024.PMID: 39114304

196. Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi

M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M.
**Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.**
Cancer. 2024 Jul 30. doi: 10.1002/cncr.35489. PMID: 39078647

195. Spampinato M, Zuppelli T, Dulcamare I, Longhitano L, Sambataro D, Santisi A, Alanazi AM, Barbagallo IA, Vicario N, Parenti R, Romano A, Musumeci G, Li Volti G, Palumbo GA, Di Raimondo F, Nicolosi A, Giallongo S, Del Fabro V.
**Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia.**
Pharmaceuticals (Basel). 2024 Jul 5;17(7):894. doi: 10.3390/ph17070894.PMID: 39065744

194. Gozzo L, Leotta S, Romano GL, Vetro C, Duminuco A, Milone G, Cupri A, Palumbo FE, Brancati S, Ruscica R, Longo L, Vitale DC, Fiorenza G, Lombardo GE, Lazzara A, Di Raimondo F, Palumbo GA, Drago F.
**Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease.**
J Clin Med. 2024 Jul 22;13(14):4273. doi: 10.3390/jcm13144273.

193. Palandri F, Branzanti F, Benevolo G, Beggiato E, Morsia E, Dedola A, Loffredo M, Fontana G, Palumbo GA, Breccia M, Tiribelli M.
**Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series.**
Br J Haematol. 2024 Jul 17. doi: 10.1111/bjh.19654. PMID: 39019815

192. Mangione R, Giallongo C, Duminuco A, La Spina E, Longhitano L, Giallongo S, Tibullo D, Lazzarino G, Saab MW, Sbriglione A, Palumbo GA, Graziani A, Alanazi AM, Di Pietro V, Tavazzi B, Amorini AM, Lazzarino G.
**Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients.**
Antioxidants (Basel). 2024 Apr 19;13(4):490. doi: 10.3390/antiox13040490.PMID: 38671937

191. Duminuco A, Romano A, Ferrarini I, Santuccio G, Chiarenza A, Figuera A, Caruso LA, Motta G, Palumbo GA, Mogno C, Moioli A, Di Raimondo F, Visco C.
**Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey.**
Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05752-6. PMID: 38630129

190. Ini' C, Foti PV, Duminuco A, Farina R, Clemenza M, Tiralongo F, David E, Palmucci S, Palumbo GA, Basile A.
**Renal extramedullary hematopoiesis as an epiphenomenon of bone marrow dysfunction in a patient with primary myelofibrosis: A rare case report.**
Radiol Case Rep. 2024 Mar 21;19(6):2286-2291. doi: 10.1016/j.radcr.2024.02.083. eCollection 2024 Jun.PMID: 38559653

189. Kuykendall AT, Ball S, Mora B, Mo Q, Al Ali N, Maffioli M, Auteri G, Mazzoni C, Palumbo GA, Duminuco A, Longo A, Elli EM, Passamonti F, Palandri F, Komrokji R.
**Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib.**
JCO Precis Oncol. 2024 Mar;8:e2300593. doi: 10.1200/PO.23.00593.PMID: 38484210

188. Palandri F, Auteri G, Abruzzese E, Caocci G, Bonifacio M, Mendicino F, Latagliata R, Iurlo A, Branzanti F, Garibaldi B, Trawinska MM, Cattaneo D, Krampera M, Mulas O, Martino EA, Cavo M, Vianelli N, Impera S, Efficace F, Heidel F, Breccia M, Elli EM, Palumbo GA.
**Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.**
Ann Hematol. 2024 Jun;103(6):1931-1940. doi: 10.1007/s00277-024-05704-0. Epub 2024 Mar 13.PMID: 38478023

187. Duminuco A, Nardo A, Palumbo GA.
**Occurrence of lymphoproliferative disorders during ruxolitinib treatment: May fedratinib be the turning point?**
Hematol Oncol. 2024 Mar;42(2):e3259. doi: 10.1002/hon.3259.PMID: 38402568

186. Duminuco A, Chifotides HT, Giallongo S, Giallongo C, Tibullo D, Palumbo GA.
**ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.**
Cancers (Basel). 2023 Dec 28;16(1):154. doi: 10.3390/cancers16010154.PMID: 38201581

185. Palandri F, Palumbo GA, Benevolo G, Iurlo A, Elli EM, Abruzzese E, Polverelli N, Tiribelli M, Auteri G, Tieghi A, Caocci G, Binotto G, Cavazzini F, Branzanti F, Beggiato E, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Scaffidi L, Venturi M, Duminuco A, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Trawinska MM, Vianelli N, Cavo M, Bonifacio M, Breccia M.
**Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.**
Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156. PMID: 38153814

184. Giallongo S, Duminuco A, Dulcamare I, Zuppelli T, La Spina E, Scandura G, Santisi A, Romano A, Di Raimondo F, Tibullo D, Palumbo GA, Giallongo C.
**Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers.**
Biomolecules. 2023 Nov 24;13(12):1701. doi: 10.3390/biom13121701.PMID: 38136573

183. Fazio M, Del Fabro V, Parrinello NL, Allegra A, Markovic U, Botta C, Accardi F, Vincelli ID, Leotta S, Elia F, Esposito B, Garibaldi B, Sapuppo G, Orofino A, Romano A, Palumbo GA, Di Raimondo F, Conticello C.
**Multiple Myeloma in 2023 Ways: From Trials to Real Life.**
Curr Oncol. 2023 Nov 3;30(11):9710-9733. doi: 10.3390/curroncol30110705.PMID: 37999125

182. Fulvio G, Baldini C, Mosca M, di Paolo A, Bocci G, Palumbo GA, Cacciola E, Migliorini P, Cacciola R, Galimberti S.
**Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?**
Front Med (Lausanne). 2023 Oct 17;10:1254868. doi: 10.3389/fmed.2023.1254868. eCollection 2023.PMID: 37915324

181. Palandri F, Palumbo GA, Bonifacio M, Elli EM, Tiribelli M, Auteri G, Trawinska MM, Polverelli N, Benevolo G, Tieghi A, Cavalca F, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Venturi M, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Branzanti F, Vianelli N, Cavo M, Heidel F, Iurlo A, Breccia M.
**A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.**
Cancers (Basel). 2023 Oct 17;15(20):5027. doi: 10.3390/cancers15205027.PMID: 37894394

180. Duminuco A, Parisi M, Milone GA, Cupri A, Leotta S, Palumbo GA, Parrinello NL, Scuderi G, Triolo A, Milone G.
**Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma.**
Hematol Rep. 2023 Oct 11;15(4):555-561. doi: 10.1038/s41419-023-06197-x.PMID: 37873793

179. Giallongo C, Dulcamare I, Giallongo S, Duminuco A, Pieragostino D, Cufaro MC, Amorini AM, Lazzarino G, Romano A, Parrinello N, Di Rosa M, Broggi G, Caltabiano R, Caraglia M, Scrima M, Pasquale LS, Tathode MS, Li Volti G, Motterlini R, Di Raimondo F, Tibullo D, Palumbo GA.
**MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.**
Cell Death Dis. 2023 Oct 18;14(10):686. doi: 10.1038/s41419-023-06197-x.PMID: 37852977

178. Palumbo GA, Duminuco A.
**Myelofibrosis: In Search for BETter Targeted Therapies.**
J Clin Oncol. 2023 Sep 26:JCO2300833. doi: 10.1200/JCO.23.00833.PMID: 37751563

177. Efficace F, Al Essa W, Platzbecker U, Niscola P, Palumbo GA, Caocci G, Cottone F, Breccia M, Luppi M, Stauder R, Ricco A, Petranovic D, Baron F, Voso MT, Fianchi L, Frairia C, Capodanno I, Sarlo C, Fedele M, Lemoli RM, Invernizzi R, Vallisa D, Di Renzo N, Fozza C, Doro M, Giesinger JM, Vignetti M.
**Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA.**
Hemasphere. 2023 Aug 30;7(9):e944. doi: 10.1097/HS9.0000000000000944. eCollection 2023 Sep.PMID: 37663671

176. Duminuco A, Nardo A, Orofino A, Giunta G, Conticello C, Del Fabro V, Chiarenza A, Parisi MS, Figuera A, Leotta S, Milone G, Cupri A, Cambria D, Di Raimondo F, Romano A, Palumbo GA.
**Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.**

Cancer. 2023 Sep 1. doi: 10.1002/cncr.35005. PMID: 37658645

175. Duminuco A, Mosquera-Orgueira A, Nardo A, Di Raimondo F, Palumbo GA.
**AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.**
Cancer Rep (Hoboken). 2023 Aug 8:e1881. doi: 10.1002/cnr2.1881. PMID: 37553891

174. Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V.
**Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.**
Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706.PMID: 37509367

173. Fazio M, Vetro C, Markovic U, Duminuco A, Parisi M, Maugeri C, Mauro E, Parrinello NL, Stagno F, Villari L, Triolo AM, Stella S, Palumbo GA, Di Raimondo F, Romano A, Zanotti R.
**A case of high-risk AML in a patient with advanced systemic mastocytosis.**
Clin Case Rep. 2023 Jul 17;11(7):e7134. doi: 10.1002/ccr3.7134. eCollection 2023 Jul.PMID: 37469366

172. Duminuco A, Torre E, Palumbo GA, Harrison C.
**A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.**
Curr Hematol Malig Rep. 2023 Oct;18(5):176-189. doi: 10.1007/s11899-023-00702-x. Epub 2023 Jul 3.PMID: 37395943

171. Pennisi MS, Di Gregorio S, Tirrò E, Romano C, Duminuco A, Garibaldi B, Giuffrida G, Manzella L, Vigneri P, Palumbo GA.
**Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the *MPL* Gene: Two Case Reports.**
Hematol Rep. 2023 May 23;15(2):317-324. doi: 10.3390/hematolrep15020033.PMID: 37367082

170. Duminuco A, Vetro C, Giallongo C, Palumbo GA.
**The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.**
Expert Opin Pharmacother. 2023 Jun 26:1-13. doi: 10.1080/14656566.2023.2228695. PMID: 37341682

169. Oliva EN, Candoni A, Salutari P, Palumbo GA, Reda G, Iannì G, Tripepi G, Cuzzola M, Capelli D, Mammì C, Alati C, Cannatà MC, Niscola P, Serio B, Musto P, Vigna E, Volpe A, Melillo LMA, Arcadi MT, Mannina D, Zannier ME, Latagliata R.
**Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).**
Cancers (Basel). 2023 Apr 24;15(9):2441. doi: 10.3390/cancers15092441.PMID: 37173908

168. Palandri F, Elli EM, Auteri G, Bonifacio M, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggiato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampera M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M.
**Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.**
Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6.PMID: 37137878

167. Duminuco A, Romano A, Sabattini E, Villari L, Del Fabro V, Elia F, Palumbo GA, Di Raimondo F, Conticello C.
**Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review.**
Acta Haematol. 2023 Apr 17. doi: 10.1159/000530601. PMID: 37068478

166. Duminuco A, Romano A, Leotta D, La Spina E, Cambria D, Bulla A, Del Fabro V, Tibullo D, Giallongo C, Palumbo GA, Conticello C, Di Raimondo F.
**Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab.**
Front Oncol. 2023 Mar 29;13:1157610. doi: 10.3389/fonc.2023.1157610. eCollection 2023.PMID: 37064138

165. Ferrero S, Grimaldi D, Arrigoni E, Pironti M, Zaccaria GM, Alessandria B, Genuardi E, De Luca G, Ghislieri M, Tavarozzi R, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli VR, Moita F, Arcaini L, Lucchini E, Ballerini F, Ferreri AJM, Puccini B, Palumbo GA, Galimberti S, Cortelazzo S, Di Paolo A, Ladetto M.
**Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial.**
Blood Adv. 2023 Apr 14:bloodadvances.2022009504. doi: 10.1182/bloodadvances.2022009504. PMID: 37058477

164. Duminuco A, Nardo A, Giuffrida G, Leotta S, Markovic U, Giallongo C, Tibullo D, Romano A, Di Raimondo F, Palumbo GA.
**Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.**
J Clin Med. 2023 Mar 11;12(6):2188. doi: 10.3390/jcm12062188.PMID: 36983189

163. Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA.
**Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.**
Cancer. 2023 Mar 18. doi: 10.1002/cncr.34722. PMID: 36932983

162. La Spina E, Giallongo S, Giallongo C, Vicario N, Duminuco A, Parenti R, Giuffrida R, Longhitano L, Li Volti G, Cambria D, Di Raimondo F, Musumeci G, Romano A, Palumbo GA, Tibullo D.
**Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases.**
Front Oncol. 2023 Feb 23;13:1141610. doi: 10.3389/fonc.2023.1141610. eCollection 2023.PMID: 36910610

161. Palumbo GA, Cambria D, La Spina E, Duminuco A, Laneri A, Longo A, Vetro C, Giallongo S, Romano A, Di Raimondo F, Tibullo D, Giallongo C.
**Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.**
Front Oncol. 2023 Feb 14;13:1117815. doi: 10.3389/fonc.2023.1117815. eCollection 2023.PMID: 36865808

160. Cambria D, Longhitano L, La Spina E, Giallongo S, Orlando L, Giuffrida R, Tibullo D, Fontana P, Barbagallo I, Nicoletti VG, Volti GL, Fabro VD, Coda ARD, Liso A, Palumbo GA.
**IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia.**
Life (Basel). 2023 Jan 17;13(2):259. doi: 10.3390/life13020259.PMID: 36836615

159. Barbato A, Giallongo C, Giallongo S, Romano A, Scandura G, Concetta S, Zuppelli T, Lolicato M, Lazzarino G, Parrinello N, Del Fabro V, Fontana P, Aguennoz M, Li Volti G, Palumbo GA, Di Raimondo F, Tibullo D.
**Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma.**
Cell Prolif. 2023 Apr;56(4):e13388. doi: 10.1111/cpr.13388. Epub 2023 Feb 15.PMID: 36794373

158. Coltro G, Sant'Antonio E, Palumbo GA, Mannelli F, De Stefano V, Ruggeri M, Elli EM, Zanotti R, Borsani O, Bertozzi I, Duminuco A, Betti S, Carli G, Cavalca F, Tanasi I, Rumi E, Randi ML, Garibaldi B, Loscocco GG, Guglielmelli P, Vannucchi AM.
**Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.**
Cancer Med. 2023 Jan 27. doi: 10.1002/cam4.5618. PMID: 36708083

157. Duminuco A, Scarso S, Cupri A, Parrinello NL, Villari L, Scuderi G, Giunta G, Leotta S, Milone GA, Giuffrida G, Palumbo GA, Milone G.
***Leishmania* Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients.**
J Clin Med. 2023 Jan 11;12(2):578. doi: 10.3390/jcm12020578.PMID: 36675507

156. Duminuco A, Nardo A, Garibaldi B, Vetro C, Longo A, Giallongo C, Di Raimondo F, Palumbo GA.
**Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.**

J Clin Med. 2022 Dec 14;11(24):7418. doi: 10.3390/jcm11247418.PMID: 36556033

155. Palumbo GA, Breccia M, Baratè C, Bonifacio M, Elli EM, Iurlo A, Pugliese N, Rossi E, Guglielmelli P, Palandri F.
**Management of polycythemia vera: A survey of treatment patterns in Italy.**
Eur J Haematol. 2022 Nov 1. doi: 10.1111/ejh.13889. PMID: 36319575

154. Carota G, Distefano A, Spampinato M, Giallongo C, Broggi G, Longhitano L, Palumbo GA, Parenti R, Caltabiano R, Giallongo S, Di Rosa M, Polosa R, Bramanti V, Vicario N, Li Volti G, Tibullo D.
**Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models**.
Antioxidants (Basel). 2022 Aug 18;11(8):1596. doi: 10.3390/antiox11081596.PMID: 36009316. Correction: Antioxidants (Basel). 2023 Dec 12;12(12):2099. doi: 10.3390/antiox12122099.PMID: 38136252

153. Breccia M, Palandri F, Guglielmelli P, Palumbo GA, Malato A, Mendicino F, Ricco A, Sant'Antonio E, Tiribelli M, Iurlo A
**Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.**
Curr Oncol. 2022 Jul 15;29(7):4970-4980. doi: 10.3390/curroncol29070395.PMID: 35877255

152. Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, Salemi D, Agueli C, Palumbo **GA**, Santoro A, Di Raimondo F, Vetro C.
**Target Therapy for Extramedullary Relapse of *FLT3*-ITD Acute Myeloid Leukemia: Emerging Data from the Field.**
Cancers (Basel). 2022 Apr 27;14(9):2186. doi: 10.3390/cancers14092186.PMID: 35565314

151. Romano A, Parrinello NL, Barchitta M, Manuele R, Puglisi F, Maugeri A, Barbato A, Triolo AM, Giallongo C, Tibullo D, La Ferla L, Botta C, Siragusa S, Iacobello C, Montineri A, Volti GL, Agodi A, Palumbo GA, Di Raimondo F.
**In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection.**
Sci Rep. 2022 May 4;12(1):7237. doi: 10.1038/s41598-022-11157-0.PMID: 35508575

150. Duminuco A, Vetro C, Maugeri C, Mauro E, Palumbo GAM, Parisi MS, Esposito B, Giuliano G, Romano A, Di Raimondo F.
***Saprochete capitata*: Emerging Infections from Uncommon Microorganisms in Hematological Diseases.**
Hematol Rep. 2022 Mar 24;14(2):67-72. doi: 10.3390/hematolrep14020011.PMID: 35466175

149. Liso A, Venuto S, Coda ARD, Giallongo C, Palumbo GA, Tibullo D.
**IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis.**
Int J Mol Sci. 2022 Apr 14;23(8):4358. doi: 10.3390/ijms23084358.PMID: 35457175

148. Scandura G, Giallongo C, Puglisi F, Romano A, Parrinello NL, Zuppelli T, Longhitano L, Giallongo S, Di Rosa M, Musumeci G, Motterlini R, Foresti R, Palumbo GA, Li Volti G, Di Raimondo F, Tibullo D.
**TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment.**
Antioxidants (Basel). 2022 Apr 12;11(4):767. doi: 10.3390/antiox11040767.PMID: 35453452

147. Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiato E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, Palumbo GA, Breccia M.
**Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis**.
Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1.PMID: 35363892

146. Vetro C, Duminuco A, Gozzo L, Maugeri C, Parisi M, Brancati S, Longo L, Vitale DC, Romano GL, Ciuni R, Mauro E, Fiumara PF, Palumbo GAM, Drago F, Di Raimondo F.
**Pegylated Asparaginase-Induced Liver Injury: A Case-Based Review and Data From Pharmacovigilance.**
J Clin Pharmacol. 2022 Mar 27. doi: 10.1002/jcph.2052. PMID: 35342960

145. Vetro C, Di Giacomo V, Mannina D, Magrin S, Mulè A, Mitra ME, Siragusa S, Duminuco A, Garibaldi B, Vadalà MCE, Di Raimondo F, Palumbo GA.
**Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.**
J Clin Med. 2022 Mar 17;11(6):1665. doi: 10.3390/jcm11061665.

144. Duminuco A, Vetro C, Markovic U, Di Raimondo F, Palumbo GAM**.**
**VEXAS-like syndrome: a potential new entity?**
Ann Hematol. 2022 Mar 22. doi: 10.1007/s00277-022-04818-7.

143. D'Amico E, Zanghì A, Parrinello NL, Romano A, Palumbo GA, Chisari CG, Toscano S, Raimondo FD, Zappia M, Patti F.
**Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.**
Front Immunol. 2022 Feb 22;13:819136. doi: 10.3389/fimmu.2022.819136. eCollection 2022.

142. Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F.
**Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.**
Cancers 2022 Feb 24;14(5):1173. doi: 10.3390/cancers14051173.

141. Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carmosino I, Benevolo G, Abruzzese E, Bonifacio M, Bergamaschi M, Polverelli N, Caramella M, Cilloni D, Tiribelli M, Pugliese N, Caocci G, Crisà E, Porrini R, Markovic U, Renso R, Auteri G, Cattaneo D, Trawinska MM, Scaffidi L, Biale L, Bucelli C, Breccia M, Gambacorti-Passerini C, Palumbo GA, Latagliata R, Palandri F
**Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.**
Br J Haematol. 2022 Feb 8. doi: 10.1111/bjh.18057

140. Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G.
**Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology.**
J Clin Med. 2022 Jan 26;11(3):623. doi: 10.3390/jcm11030623.PMID: 35160072

139. Giallongo C, Dulcamare I, Tibullo D, Del Fabro V, Vicario N, Parrinello N, Romano A, Scandura G, Lazzarino G, Conticello C, Li Volti G, Amorini AM, Musumeci G, Di Rosa M, Polito F, Oteri R, Aguennouz M, Parenti R, Di Raimondo F, Palumbo GA**.**
**CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.**
Oncogenesis. 2022 Jan 21;11(1):6. doi: 10.1038/s41389-022-00380-z.PMID: 35064098

138. Longhitano L, Tibullo D, Vicario N, Giallongo C, La Spina E, Romano A, Lombardo S, Moretti M, Masia F, Coda ARD, Venuto S, Fontana P, Parenti R, Li Volti G, Di Rosa M, Palumbo GA, Liso A.
**IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.**
Aging 2021 Dec 14;13(23):25055-25071. doi: 10.18632/aging.203779. Epub 2021 Dec 14.PMID: 34905501

137. Duminuco A, Mauro E, Palumbo GAM, Garibaldi B, Parisi M, Di Raimondo F, Maugeri C, Vetro C
**Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association.**
Hematol Rep. 2021 Nov 26;13(4):9329. doi: 10.4081/hr.2021.9329. eCollection 2021 Nov 26.PMID: 35070221

136. Gozzo L, Vetro C, Brancati S, Longo L, Vitale DC, Romano GL, Mauro E, Fiumara PF, Maugeri C, Parisi MS, Dulcamare I, Garibaldi B, Duminuco A, Palumbo GA, Di Raimondo F, Drago F.
**Off-Label Use of Venetoclax in Patients with Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.**
Front Pharmacol. 2021 Nov 11;12:748766. doi: 10.3389/fphar.2021.748766. eCollection 2021.PMID: 34899303

135. Palumbo GA, Galimberti S, Barcellini W, Cilloni D, Di Renzo N, Elli EM, Finelli C, Maurillo L, Ricco A, Musto P, Russo R, Latagliata R
**From Biology to Clinical Practice: Iron Chelation Therapy with Deferasirox.**
Front Oncol. 2021 Oct 6;11:752192. doi: 10.3389/fonc.2021.752192. eCollection 2021.

134. Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, Palumbo GA, Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M.
**Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).**
Leuk Lymphoma. 2021 Sep 15:1-10. doi: 10.1080/10428194.2021.1969388.PMID: 34521299

133. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, Palumbo GA, Spencer A, Boccadoro M, Cavo M.
**Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.**
J Clin Oncol. 2021 Sep 14:JCO2101045. doi: 10.1200/JCO.21.01045.PMID: 34520219

132. Oliva EN, Latagliata R, Sabattini E, Mammì C, Cuzzola M, D'Errigo MG, Cannatà MC, Bova I, Capodanno I, Palumbo GA, Pane F, Reda G, Fianchi L, Riva M, Poloni A.
**Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.**
Am J Blood Res. 2021 Aug 15;11(4):417-426. eCollection 2021.PMID: 34540351

131. Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M.
**Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.**
Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.PMID: 33937048

130. Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA.
**Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.**
Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. PMID: 33794557

129. Gamper EM, Cottone F, Sommer K, Norman R, King M, Breccia M, Caocci G, Patriarca A, Palumbo GA, Stauder R, Niscola P, Platzbecker U, Caers J, Vignetti M, Efficace F.
**The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.**
J Clin Epidemiol. 2021 Mar 20;137:31-44. doi: 10.1016/j.jclinepi.2021.03.015. PMID: 33753228

128. Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F.
**Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.**
Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843.

127. Spampinato M, Giallongo C, Romano A, Longhitano L, La Spina E, Avola R, Scandura G, Dulcamare I, Bramanti V, Di Rosa M, Vicario N, Parenti R, Li Volti G, Tibullo D, Palumbo GA.
**Focus on Osteosclerotic Progression in Primary Myelofibrosis.**
Biomolecules. 2021 Jan 19;11(1):122. doi: 10.3390/biom11010122.PMID: 33477816

126. Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M.
**Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.**
Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.PMID: 33414394

125. Stella S, Massimino M, Manzella L, Pennisi MS, Tirrò E, Romano C, Vitale SR, Puma A, Tomarchio C, Gregorio SD, Palumbo GA, Vigneri P.
**Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.**
Int J Mol Sci. 2021 Jan 6;22(2):486. doi: 10.3390/ijms22020486.PMID: 33418988

124. Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F.
**Second primary malignancy in myelofibrosis patients treated with ruxolitinib.**
Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.PMID: 3322219.

123. Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, Lazzarino G, Tibullo D, Di Raimondo F, Giallongo C, Romano A.
**Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview.**
Front Oncol. 2020 Dec 21;10:604143. doi: 10.3389/fonc.2020.604143. eCollection 2020.PMID: 33409153

122. Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Giai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V.
**SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot from early Italian experience.**
Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. PMID: 33062948; PMCID: PMC7523798.

121. Longhitano L, Li Volti G, Giallongo C, Spampinato M, Barbagallo I, Di Rosa M, Romano A, Avola R, Tibullo D, Palumbo GA.
**The Role of Inflammation and Inflammasome in Myeloproliferative Disease.**
J Clin Med. 2020 Jul 22;9(8):2334. doi: 10.3390/jcm9082334.PMID: 32707883

120. Giallongo C, Tibullo D, Puglisi F, Barbato A, Vicario N, Cambria D, Parrinello NL, Romano A, Conticello C, Forte S, Parenti R, Amorini AM, Lazzarino G, Li Volti G, Palumbo GA, Di Raimondo F.
**Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells.**
Cancers (Basel). 2020 Jul 22;12(8):1999. doi: 10.3390/cancers12081999.PMID: 32707760

119. Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F.
**High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity.**
Int J Hematol. 2020 Aug;112(2):141-146. doi: 10.1007/s12185-020-02920-y. Epub 2020 Jun 25.PMID: 32588394

118. Camiolo G, Barbato A, Giallongo C, Vicario N, Romano A, Parrinello NL, Parenti R, Sandoval JC, García-Moreno D, Lazzarino G, Avola R, Palumbo GA, Mulero V, Li Volti G, Tibullo D, Di Raimondo F.
**Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib.**
Redox Biol. 2020 Sep;36:101611. doi: 10.1016/j.redox.2020.101611. Epub 2020 Jun 24.PMID: 32863212

117. Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N.
**Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.**
Int J Mol Sci. 2020 May 30;21(11):3900. doi: 10.3390/ijms21113900.PMID: 32486130

116. Longhitano L, Tibullo D, Giallongo C, Lazzarino G, Tartaglia N, Galimberti S, Li Volti G, Palumbo GA, Liso A.
**Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.**
Int J Mol Sci. 2020 May 20;21(10):3622. doi: 10.3390/ijms21103622.PMID: 32443911

115. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM,

Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P.
**Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.**
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.PMID: 32359506

114. Tibullo D, Giallongo C, Romano A, Vicario N, Barbato A, Puglisi F, Parenti R, Amorini AM, Wissam Saab M, Tavazzi B, Mangione R, Brundo MV, Lazzarino G, Palumbo GA, Volti GL, Raimondo FD, Lazzarino G.
**Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.**
Biomolecules. 2020 Apr 30;10(5):696. doi: 10.3390/biom10050696.PMID: 32365811

113. Di Rosa M, Giallongo C, Romano A, Tibullo D, Li Volti G, Musumeci G, Barbagallo I, Imbesi R, Castrogiovanni P, Palumbo GA.
**Immunoproteasome Genes Are Modulated in CD34$^{+}$ JAK2$^{V617F}$ Mutated Cells from Primary Myelofibrosis Patients.**
Int J Mol Sci. 2020 Apr 22;21(8). pii: E2926. doi: 10.3390/ijms21082926

112. Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA.
**Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.**
Hematol Oncol. 2020 Apr 9. doi: 10.1002/hon.2737. [Epub ahead of print]

111. Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M.
**The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index.**
Leukemia. 2020 Feb 21. doi: 10.1038/s41375-020-0746-8.

110. Romano A, Parrinello NL, Simeon V, Puglisi F, La Cava P, Bellofiore C, Giallongo C, Camiolo G, D'Auria F, Grieco V, Larocca F, Barbato A, Cambria D, La Spina E, Tibullo D, Palumbo GA, Conticello C, Musto P, Di Raimondo F.
**High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.**
Sci Rep. 2020 Feb 6;10(1):1983. doi: 10.1038/s41598-020-58859-x.

109. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM.
**Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.**
Br J Haematol. 2020 Feb 4. doi: 10.1111/bjh.16462.

108. Tibullo D, Longo A, Vicario N, Romano A, Barbato A, Di Rosa M, Barbagallo I, Anfuso CD, Lupo G, Gulino R, Parenti R, Li Volti GL, Palumbo GA, Di Raimondo FD, Giallongo C.
**Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells.**
Cancers (Basel). 2020 Jan 30;12(2). pii: E323. doi: 10.3390/cancers12020323.

107. Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N.
**Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.**
Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.

106. Breccia M, Baratè C, Benevolo G, Bonifacio M, Elli EM, Guglielmelli P, Maffioli M, Malato A, Mendicino F, Palumbo GA, Pugliese N, Rossi E, Rumi E, Sant'Antonio E, Ricco A, Tiribelli M, Palandri F.
**Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.**
Ann Hematol. 2020 Jan;99(1):65-72. doi: 10.1007/s00277-019-03847-z. Epub 2019 Dec 12.

105. Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA.
**Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.**
Front Oncol. 2019 Nov 7;9:1186. doi: 10.3389/fonc.2019.01186. eCollection 2019.

104. Palumbo GA, Parrinello NL, Giallongo C, D'Amico E, Zanghì A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Raimondo FD, Romano A.
**Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.**
Int J Mol Sci. 2019 Nov 1;20(21). pii: E5459. doi: 10.3390/ijms20215459.

103. Giallongo C, Tibullo D, Camiolo G, Parrinello NL, Romano A, Puglisi F, Barbato A, Conticello C, Lupo G, Anfuso CD, Lazzarino G, Li Volti G, Palumbo GA, Di Raimondo F.
**TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma.**
Cell Death Dis. 2019 Sep 20;10(10):704. doi: 10.1038/s41419-019-1959-5. Correction: Cell Death Dis. 2019 Oct 28;10(11):820. doi: 10.1038/s41419-019-2059-2.

102. D'Amico E, Zanghì A, Romano A, Sciandra M, Palumbo GAM, Patti F.
**The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis.**
Cells. 2019 Sep 20;8(10). pii: E1114. doi: 10.3390/cells8101114.

101. Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C.
**Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.**
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fo

100. Bereshchenko O, Lo Re O, Nikulenkov F, Flamini S, Kotaskova J, Mazza T, Le Pannérer MM, Buschbeck M, Giallongo C, Palumbo G, Li Volti G, Pazienza V, Cervinek L, Riccardi C, Krejci L, Pospisilova S, Stewart AF, Vinciguerra M.
**Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.**
Clin Epigenetics. 2019 Aug 22;11(1):121. doi: 10.1186/s13148-019-0724-z.

99. Puglisi F, Parrinello NL, Giallongo C, Cambria D, Camiolo G, Bellofiore C, Conticello C, Del Fabro V, Leotta V, Markovic U, Sapienza G, Barbato A, Scalese S, Tibullo D, Brundo MV, Palumbo GA, Di Raimondo F, Romano A.
**Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3.**
Int J Mol Sci. 2019 Jul 19;20(14):3548. doi: 10.3390/ijms20143548.PMID: 32565533

98. Palumbo GA, Stella S, Pennisi MS, Pirosa C, Fermo E, Fabris S, Cattaneo D, Iurlo A.
**The Role of New Technologies in Myeloproliferative Neoplasms.**
Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019.

97. Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.
**Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.**
Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619.

96. Pappalardo A, Currenti W, Ponzio R, Mellini G, Nicolosi D, Longhitano L, Tibullo D, Castorina S, Palumbo G.
**Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study.**

Blood Transfus. 2019 May;17(3):196-199. doi: 10.2450/2019.0181-18. Epub 2019 Feb 18.

95. Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.
**Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.**
Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.

94. Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.
**Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.**
Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801. Epub 2019 Feb 15.

93. Camiolo G, Tibullo D, Giallongo C, Romano A, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA.
**α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.**
Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609.

92. Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.
**Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.**
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

91. Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.
**Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.**
Ann Hematol. 2018 Dec 4. doi: 10.1007/s00277-018-3569-1. [Epub ahead of print]

90. Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.
**Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.**
Blood Rev. 2018 Oct 28. pii: S0268-960X(18)30069-9. doi: 10.1016/j.blre.2018.10.002. [Epub ahead of print] Review.

89. Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatici A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.
**Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.**
Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5.

88. Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.
**Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.**
Br J Haematol. 2018 Jul 16. doi: 10.1111/bjh.15497. [Epub ahead of print]

87. Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D.
**The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.**
Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15450. [Epub ahead of print]

86. Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.
**PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.**
Expert Rev Mol Diagn. 2018 May 3:1-9. doi: 10.1080/14737159.2018.1470929. [Epub ahead of print]

85. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.
**Iron toxicity - Its effect on the bone marrow.**
Blood Rev. 2018 Apr 13. pii: S0268-960X(17)30150-9. doi: 10.1016/j.blre.2018.04.004. [Epub ahead of print]

84. Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.
**Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.**
Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

83. Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.
**Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.**
Qual Life Res. 2018 Mar 8. doi: 10.1007/s11136-018-1827-2. [Epub ahead of print]

82. Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, Castagnetti F, Palumbo GA, Iurlo A, Landi F.
**Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.**
Ann Hematol. 2018 May;97(5):745-754. doi: 10.1007/s00277-018-3258-0. Epub 2018 Feb 22. Review.

81. Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F.
**Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.**
Ann Hematol. 2018 Feb 14. doi: 10.1007/s00277-018-3276-y. [Epub ahead of print]

80. Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.
**Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.**
Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

79. Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F.
**Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.**
J Cell Mol Med. 2018 Feb;22(2):1070-1080. doi: 10.1111/jcmm.13326. Epub 2017 Dec 8.

78. Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.
**Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.**
Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.

77. Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.
**Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.**
Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

76. Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M.
**Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.**
Hematol Oncol. 2017 May 17. doi: 10.1002/hon.2429. [Epub ahead of print]

75. Latagliata R, Polverelli N, Tieghi A, Palumbo GA, Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.
**Comparison of JAK2$^{V617F}$-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.**
Hematol Oncol. 2017 May 16. doi: 10.1002/hon.2430. [Epub ahead of print]

74. Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA.
**Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.**
Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

73. Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, Palumbo GA, Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.
**Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.**
Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3

72. Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F.
**Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.**
PLoS One. 2016 Jul 8;11(7):e0158392. doi: 10.1371/journal.pone.0158392. eCollection 2016.

71. Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, Avola R, Romano A, Di Raimondo F.
**Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC).**
Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7969. [Epub ahead of print]

70. Vetro C, Rosso R, Palmucci S, Russello M, Colletta G, Romeo MA, Ximenes B, Romano A, Palumbo GA, Di Raimondo F.
**Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome.**
J Clin Apher. 2015 Sep 28. doi: 10.1002/jca.21434. [Epub ahead of print]

69. Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.
**Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.**
Lancet Oncol. 2015 Sep 21. pii: S1470-2045(15)00206-5. doi: 10.1016/S1470-2045(15)00206-5. [Epub ahead of print]

68. Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R.
**Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.**
Cancer Med. 2015 Sep 17. doi: 10.1002/cam4.523. [Epub ahead of print]

67. Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F.
**Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.**
Leuk Res. 2015 Jun 12. pii: S0145-2126(15)00184-8. doi: 10.1016/j.leukres.2015.05.012. [Epub ahead of print]

66. Savlı H, Galimberti S, Sünnetçi D, Canesastraro M, Palumbo G, Nagy B, Di Raimondo F, Petrini M.
**Bortezomib and Arsenic Trioxide (ATO) Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.**
Turk J Haematol. 2015 Apr 27. doi: 10.4274/tjh.2014.0058. [Epub ahead of print]

65. Rossi D, Bruscaggin A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldero G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA.
**The genotype of MLH1 identifies a subgroup of follicular lymphoma patients that do not benefit from doxorubicin: FIL-FOLL05 study.**
Haematologica. 2015 Jan 16. pii: haematol.2014.108183. [Epub ahead of print]

64. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD.
**Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.**
Br J Haematol. 2015 Mar;168(5):689-700. doi: 10.1111/bjh.13198. Epub 2014 Nov 7.

63. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M.
**Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.**
Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.

62. Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Di Raimondo C, Giulietti G, Bonanno G, Palumbo GA, Di Raimondo F.
**Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.**
World J Gastroenterol. 2014 Sep 28;20(36):12993-3005. doi: 10.3748/wjg.v20.i36.12993.

61. Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F.
**Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.**
Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.

60. Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F.
**Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.**
PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014.

59. Romano A, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Cunsolo R, Palumbo GA, Di Raimondo F.
**Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.**
Eur J Haematol. 2014 Mar 27. doi: 10.1111/ejh.12325. [Epub ahead of print]

58. Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U.

**Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.**
Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.

57. Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.
**Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.**
Exp Hematol. 2014 Feb;42(2):126-136.e1. doi: 10.1016/j.exphem.2013.10.007. Epub 2013 Nov 6.

56. Giallongo C, La Cava P, Tibullo D, Barbagallo I, Parrinello N, Cupri A, Stagno F, Consoli C, Chiarenza A, Palumbo GA, Di Raimondo F.
**SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.**
BMC Cancer. 2013 Feb 5;13:60. doi: 10.1186/1471-2407-13-60.

55. Romano A, Chiarenza A, Consoli U, Conticello C, Forte S, Uccello G, Vetro C, Cavalli M, Coppolino F, Palumbo GA, Di Raimondo F.
**Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.**
Ann Oncol. 2013 Apr;24(4):1038-44. doi: 10.1093/annonc/mds531. Epub 2012 Nov 7.

54. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L, Stagno F, Palumbo GA, Li Volti G, Di Raimondo F.
**Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.**
Curr Pharm Des. 2013;19(15):2765-70.

53. Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R.
**Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.**
Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16.

52. Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A.
**Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.**
J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.

51. Vetro C, Romano A, Chiarenza A, Conticello C, Donnarumma D, Gorgone A, Coppolino F, Palumbo GA, Bonanno G, Di Raimondo F
**Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.**
Hematol Oncol. 2011 Dec 20. doi: 10.1002/hon.1022. [Epub ahead of print]

50. Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F.
**BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint.**
Acta Haematol. 2011;126(4):205-10. Epub 2011 Sep 16. Erratum in: Acta Haematol. 2011;126(4):210.

49. Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V.
**13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.**

Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11.

48. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F.
**Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.**
Hematol Oncol. 2011 May 5. doi: 10.1002/hon.988. [Epub ahead of print]

47. Milone G, Poidomani M, Leotta S, Avola G, Camuglia MG, Privitera A, Consoli C, Mercurio S, Romeo MA, Di Marco A, Di Mercurio S, Spadaro A, Palumbo GA, Tedeschi P.
**Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.**
Bone Marrow Transplant. 2012 Jan;47(1):24-32. doi: 10.1038/bmt.2011.33. Epub 2011 Mar 14.

46. Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F.
**Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.**
Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8.

45. Galimberti S, Canestraro M, Savli H, Palumbo GA, Tibullo D, Nagy B, Piaggi S, Guerrini F, Cine N, Metelli MR, Petrini M.
**ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.**
Anticancer Res. 2010 Nov;30(11):4525-35.

44. Barresi V, Romano A, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo G, Di Raimondo F, Condorelli DF.
**Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.**
Genes Chromosomes Cancer. 2010 Nov;49(11):1014-23.

43. Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, Romano A, Di Raimondo F, Condorelli DF.
**Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.**
Leuk Res. 2010 Nov;34(11):1539-42. Epub 2010 Aug 1.

42. Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N, Metelli MR, Petrini M.
**Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.**
Cancer Genet Cytogenet. 2010 Jun;199(2):110-20.

41. Galimberti S, Nagy B, Palumbo GA, Ciancia E, Buda G, Orciuolo E, Melosi A, Lambelet P, Ronca F, Petrini M.
**Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.**
Acta Haematol. 2010;123(2):91-5. Epub 2009 Dec 19.

40. Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Raimondo FD, Abraham NG, Asprinio D.
**Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.**
J Bone Miner Metab. 2010 May;28(3):276-88. Epub 2009 Nov 19.

39. Di Pietro C, Ragusa M, Barbagallo D, Duro LR, Guglielmino MR, Majorana A, Angelica R, Scalia M, Statello L, Salito L, Tomasello L, Pernagallo S, Valenti S, D'Agostino V, Triberio P, Tandurella I, Palumbo GA, La Cava P, Cafiso V, Bertuccio T, Santagati M, Li Destri G, Lanzafame S, Di Raimondo F, Stefani S, Mishra B, Purrello M.
**The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma.**
BMC Med Genomics. 2009 Apr 30;2(1):20.

38. Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F.
**Effects of imatinib mesylate in osteoblastogenesis.**
Exp Hematol. 2009 Apr;37(4):461-8.

37. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J.
**M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.**
J Immunol. 2009 Apr 1;182(7):4415-22.

36. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, Conticello C, Villari L, Di Raimondo F.
**CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.**
Leuk Res. 2009 Sep;33(9):1212-6. Epub 2009 Feb 20.

35. Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, Caruso L, Moschetti G, Cupri A, Palumbo GA, Gulisano M, De Maria R, Giustolisi R, Di Raimondo F.
**Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.**
Acta Haematol. 2008;120(1):19-30. Epub 2008 Aug 21.

34. Barbagallo I, Tibullo D, Di Rosa M, Giallongo C, Palumbo GA, Raciti G, Campisi A, Vanella A, Green CJ, Motterlini R.
**A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells.**
J Neurosci Res. 2008 Jul;86(9):1927-35.

33. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foa R, Rambaldi A.
**FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.**
Haematologica. 2007 Aug;92(8):1127-30.

32. Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M.
**The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.**
J Chemother. 2007 Jun;19(3):315-21.

31. Di Raimondo F, Caruso L, Bonanno G, Naso P, Chiarenza A, Fiumara P, Bari A, Palumbo G, Russo A, Giustolisi R.
**Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?**
Ann Oncol. 2007 Feb;18(2):351-6. Epub 2006 Oct 25.

30. Di Raimondo F, Pennisi A, Bari A, Fiumara P, Palumbo GA.
**Management of multiple myeloma.**
G Ital Nefrol. 2005 Nov-Dec;22 Suppl 33:S46-52.

29. Malaguarnera L, Pilastro MR, Vicari L, Dimarco R, Manzella L, Palumbo G, Messina A.

**Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity.**
Cancer Invest. 2005;23(5):404-12.

28. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M.
**Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.**
Leuk Res. 2004 Apr;28(4):367-72.

27. Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, Di Raimondo F, Stagno F, Guglielmo P, Giustolisi R.
**Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.**
Leuk Res. 2004 May;28(5):469-77.

26. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, Petrini M.
**Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.**
Eur J Haematol. 2004 Jan;72(1):45-51.

25. Galimberti S, Rossi A, Palumbo GA, Morabito F, Guerrini F, Vincelli I, Fazzi R, Santini V, Petrini M.
**FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.**
Anticancer Res. 2003 Jul-Aug;23(4):3419-26.

24. Galimberti S, Guerrini F, Morabito F, Palumbo GA, Di Raimondo F, Papineschi F, Caracciolo F, Fazzi R, Cervetti G, Cuzzocrea A, Petrini M.
**Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab.**
Bone Marrow Transplant. 2003 Jul;32(1):57-63.

23. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzara A, Martino M, Benedetti E, Di Raimondo F, Petrini M.
**Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.**
Br J Haematol. 2003 Feb;120(3):405-12.

22. Milone G, Di Raimondo F, Gioi FL, Palumbo GA, Manenti GO, Pafumi M, Giustolisi R.
**Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.**
Leuk Lymphoma. 2002 Dec;43(12):2319-24.

21. Consoli U, Milone G, Guido G, Consoli C, Palumbo GA, Giustolisi R.
**STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a CML patient relapsing with accelerated phase after allogeneic stem cell transplantation.**
Haematologica. 2002 Dec;87(12):ECR37.

20. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, Giustolisi GM, Pavone B, Palumbo GA, Di Raimondo F, Milone G, Guglielmo P, Giustolisi R.
**Multidrug resistance mechanisms in chronic lymphocytic leukaemia.**
Br J Haematol. 2002 Mar;116(4):774-80.

19. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R.
**Angiogenesis in chronic myeloproliferative diseases.**
Acta Haematol. 2001;106(4):177-83. Review.

18. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, Cacciola E, Sortino G, Guglielmo P, Giustolisi R.
**Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.** Leukemia. 2001 Jun;15(6):976-80.

17. Shteper PJ, Siegfried Z, Asimakopoulos FA, Palumbo GA, Rachmilewitz EA, Ben-Neriah Y, Ben-Yehuda D.
**ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.**
Leukemia. 2001 Apr;15(4):575-82.

16. Di Raimondo F, Palumbo GA, Azzaro MP, Giustolisi R.
**Angiogenesis in acute myeloid leukemia.**
Blood. 2000 Nov 15;96(10):3656-7.

15. Stagno F, Guglielmo P, Consoli U, Inghilterra G, Giustolisi GM, Palumbo GA, Giustolisi R.
**In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside.**
Acta Haematol. 2000;104(2-3):57-64.

14. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
**Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.**
Haematologica. 2000 Aug;85(8):800-5.

13. Aksentijevich I, Torosyan Y, Samuels J, Centola M, Pras E, Chae JJ, Oddoux C, Wood G, Azzaro MP, Palumbo G, Giustolisi R, Pras M, Ostrer H, Kastner DL.
**Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population.**
Am J Hum Genet. 1999 Apr;64(4):949-62.

12. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, Sahar D, Rosenbaum H, Paltiel O, Zion M, Ben-Neriah Y.
**Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia.**
Blood. 1997 Dec 15;90(12):4918-23.

11. Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron N, Levitzki A, Ben-Yehuda D.
**The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2.**
Cancer Res. 1997 Jun 15;57(12):2434-9.

10. Di Raimondo F, Palumbo GA, Romeo MA, Galvagno F, Stagno F, Morabito F, Giustolisi R.
**Evaluation of Taxol cytotoxicity on B-CLL cells in vitro.**
Leuk Lymphoma. 1997 Jun;26(1-2):115-9.

9. Palumbo GA, Romeo MA, Di Raimondo F, Giustolisi R.
**Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia.**
Br J Haematol. 1997 Mar;96(4):876-7.

8. Di Raimondo F, Longo G, Cacciola E Jr, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R.

**A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study.**
Eur J Haematol. 1996 Jan-Feb;56(1-2):7-11.

7. Di Raimondo F, Palumbo GA, Romeo MA, Cacciola E, Milone G, Impera S, Giustolisi R, Cacciola E.
**In vitro sensitivity of B-CLL cells to fludarabine and interferons.**
Leuk Lymphoma. 1995 May;17(5-6):449-53.

6. Tedeschi A, Palumbo G, Milazzo N, Miadonna A.
**Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor.**
J Allergy Clin Immunol. 1994 Feb;93(2):526-33.

5. Morale MC, Guarcello V, Bartoloni G, Raiti F, Cutuli N, Palumbo G Jr, Farinella Z, Marchetti B.
**Peptidergic modulation of immune system development: role of luteinizing hormone-releasing hormone.**
Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:97-8.

4. Palumbo G Jr, Morale MC, Guarcello V, Cutuli N, Raiti F, Farinella Z, Marchetti B.
**Neuroendocrine modulation of lymphocyte's activity during the physiological menstrual cycle.**
Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:101-2.

3. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Palumbo G Jr, Raiti F, Cutuli N, Farinella Z, Scapagnini U.
**A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus gland function.**
Int J Neurosci. 1990 Apr;51(3-4):287-9.

2. Marchetti B, Morale MC, Guarcello V, Cutuli N, Raiti F, Batticane N, Palumbo G Jr, Farinella Z, Scapagnini U.
**Cross-talk communication in the neuroendocrine-reproductive-immune axis. Age-dependent alterations in the common communication networks.**
Ann N Y Acad Sci. 1990;594:309-25.

1. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G Jr, Farinella Z, Cordaro S, Scapagnini U.
**Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.**
Endocrinology. 1989 Aug;125(2):1037-45.

**MONOGRAFIE**

5. Romano A., Barresi V., Consoli C., Musso N., Capizzi C., Palumbo G.A., Di Raimondo F. and Condorelli D.F.
**Conventional and molecular cytogenetic techniques and their application in Myelodysplastic Syndromes.**
In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy- Chapter 6, NOVA Publishers, ISBN 978-1-62417-580-0, edited by Hamid Sayar (Indiana University Simon Cancer Center, Indianapolis, IN, USA)

4. Palumbo G.A.
**Splenomegalie.**
In Bosi A., De Stefano V., Di Raimondo F., La Nasa G MANUALE DI MALATTIE DEL SANGUE, 2012, Elsevier, ISBN: 9788821432620.

3. Palumbo G.A., Vetro C., Di Raimondo F.
***Linfomi*.**
*I*n Bosi A., De Stefano V., Di Raimondo F., La Nasa G MANUALE DI MALATTIE DEL SANGUE, 2012, Elsevier, ISBN: 9788821432620.

2. Vetro C., Romano A., Palumbo G.A., Bonanno G. and Di Raimondo F.
**Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature.**
In Ultrasound Imaging - Medical Applications ISBN 978-953-307-279-1, Edited by: Igor V. Minin and Oleg V. Minin, InTech (2011)

1. Palumbo G.A., Cacciola E., Guglielmo P., Giustolisi R., Cacciola E. (1994). **RELATIONSHIP BETWEEN GROWTH FACTORS, ONCOGENES AND CYTOKINES IN THE MECHANISM OF ABERRANT HEMATOPOIESIS.**
In Cacciola E., Deisseroth A.B., Giustolisi R. (Eds.): HEMOPOIETIC GROWTH FACTORS, ONCOGENES AND CYTOKINES IN CLINICAL HEMATOLOGY. Basel, Karger, 1994, pp. 1-21.

**COLLABORAZIONI A LAVORI IN EXTENSO PRESENTI SU MEDLINE**

2. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.
**Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program.**
Cancer. 2010 Mar 15;116(6):1485-94.

1. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL).
**Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.**
Blood. 2008 Apr 15;111(8):4004-13. Epub 2008 Jan 31.

***Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali***

31 maggio 2025